167 related articles for article (PubMed ID: 10618531)
21. Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection.
Tamura S; Iwasaki T; Thompson AH; Asanuma H; Chen Z; Suzuki Y; Aizawa C; Kurata T
J Gen Virol; 1998 Feb; 79 ( Pt 2)():291-9. PubMed ID: 9472613
[TBL] [Abstract][Full Text] [Related]
22. Mucosal immunity: regulation by helper T cells and a novel method for detection.
Jackson RJ; Marinaro M; VanCott JL; Yamamoto M; Okahashi N; Fujihashi K; Kiyono H; Chatfield SN; McGhee JR
J Biotechnol; 1996 Jan; 44(1-3):209-16. PubMed ID: 8717406
[TBL] [Abstract][Full Text] [Related]
23. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination.
Hirabayashi Y; Kurata H; Funato H; Nagamine T; Aizawa C; Tamura S; Shimada K; Kurata T
Vaccine; 1990 Jun; 8(3):243-8. PubMed ID: 2363302
[TBL] [Abstract][Full Text] [Related]
24. Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation.
Kadowaki S; Chen Z; Asanuma H; Aizawa C; Kurata T; Tamura S
Vaccine; 2000 Jun; 18(25):2779-88. PubMed ID: 10812219
[TBL] [Abstract][Full Text] [Related]
25. Intranasal coadministration of Cholera toxin with amoeba lysates modulates the secretion of IgA and IgG antibodies, production of cytokines and expression of pIgR in the nasal cavity of mice in the model of Naegleria fowleri meningoencephalitis.
Carrasco-Yepez M; Campos-Rodriguez R; Lopez-Reyes I; Bonilla-Lemus P; Rodriguez-Cortes AY; Contis-Montes de Oca A; Jarillo-Luna A; Miliar-Garcia A; Rojas-Hernandez S
Exp Parasitol; 2014 Nov; 145 Suppl():S84-92. PubMed ID: 24731967
[TBL] [Abstract][Full Text] [Related]
26. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine.
Tamura SI; Samegai Y; Kurata H; Kikuta K; Nagamine T; Aizawa C; Kurata T
Vaccine; 1989 Jun; 7(3):257-62. PubMed ID: 2781859
[TBL] [Abstract][Full Text] [Related]
28. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit.
Tamura S; Ito Y; Asanuma H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
J Immunol; 1992 Aug; 149(3):981-8. PubMed ID: 1634780
[TBL] [Abstract][Full Text] [Related]
29. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella.
VanCott JL; Staats HF; Pascual DW; Roberts M; Chatfield SN; Yamamoto M; Coste M; Carter PB; Kiyono H; McGhee JR
J Immunol; 1996 Feb; 156(4):1504-14. PubMed ID: 8568254
[TBL] [Abstract][Full Text] [Related]
30. IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection.
Arulanandam BP; Raeder RH; Nedrud JG; Bucher DJ; Le J; Metzger DW
J Immunol; 2001 Jan; 166(1):226-31. PubMed ID: 11123296
[TBL] [Abstract][Full Text] [Related]
31. Oral immunization with the saliva-binding region of Streptococcus mutans AgI/II genetically coupled to the cholera toxin B subunit elicits T-helper-cell responses in gut-associated lymphoid tissues.
Toida N; Hajishengallis G; Wu HY; Russell MW
Infect Immun; 1997 Mar; 65(3):909-15. PubMed ID: 9038296
[TBL] [Abstract][Full Text] [Related]
32. Intranasal trans-sialidase-based vaccine against Trypanosoma cruzi triggers a mixed cytokine profile in the nasopharynx-associated lymphoid tissue and confers local and systemic immunogenicity.
Pacini MF; Balbi CB; Dinatale B; González FB; Prochetto E; De Hernández MA; Cribb P; Farré C; Espariz M; Blancato VS; Magni C; Marcipar I; Pérez AR
Acta Trop; 2023 May; 241():106889. PubMed ID: 36893830
[TBL] [Abstract][Full Text] [Related]
33. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit.
Tamura S; Samegai Y; Kurata H; Nagamine T; Aizawa C; Kurata T
Vaccine; 1988 Oct; 6(5):409-13. PubMed ID: 2848377
[TBL] [Abstract][Full Text] [Related]
34. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
35. Oral vaccine models: multiple delivery systems employing tetanus toxoid.
Jackson RJ; Staats HF; Xu-Amano J; Takahashi I; Kiyono H; Hudson ME; Gilley RM; Chatfield SN; McGhee JR
Ann N Y Acad Sci; 1994 Aug; 730():217-34. PubMed ID: 8080173
[TBL] [Abstract][Full Text] [Related]
36. Serum antibody response and nasal lymphoid tissue (NALT) structure in the absence of IL-4 or IFN-gamma.
Andoh A; Masuda A; Kumazawa Y; Kasajima T
Cytokine; 2002 Nov; 20(3):107-12. PubMed ID: 12453468
[TBL] [Abstract][Full Text] [Related]
37. Mucosal immunity of nasopharynx: an experimental study in TCR-transgenic (OVA23-3) mice.
Yamada T; Kataoka S; Ogasawara K; Ishimitsu R; Hashigucci K; Suzuki T; Kawauchi H
Rhinology; 2005 Sep; 43(3):190-8. PubMed ID: 16218512
[TBL] [Abstract][Full Text] [Related]
38. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine.
Hagiwara Y; Komase K; Chen Z; Matsuo K; Suzuki Y; Aizawa C; Kurata T; Tamura S
Vaccine; 1999 Jul; 17(22):2918-26. PubMed ID: 10438064
[TBL] [Abstract][Full Text] [Related]
39. Nasal immune system: distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively.
Hiroi T; Iwatani K; Iijima H; Kodama S; Yanagita M; Kiyono H
Eur J Immunol; 1998 Oct; 28(10):3346-53. PubMed ID: 9808204
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
